Earnings call transcript: Nykode Therapeutics rises on q2 2026 vaccine progress

Nykode Therapeutics reported a $7.2 million net loss for Q2 2026 in its earnings call transcript, despite increased clinical spending tied to its lead cancer vaccine trial, Abili-T. The company's shares rose 4.3% to $77, nearing its 52-week high. Nykode's cash position of NOK 44.8 million should support operations until 2028, potentially extending to 2029 if a favorable tax case outcome is secured.

The company's equity ratio stands at 93%, with total equity at NOK 80 million. Despite the net loss, Nykode's financial profile remains strong for a development-stage biotech. The company's focus is now primarily on Abili-T, a randomized Phase II trial in first-line head and neck cancer, with expanded enrollment in four countries.

Management highlighted manufacturing progress, stating that its individualized neoantigen program can now move from biopsy to vaccine injection in under six weeks. The company's positive outlook is supported by recent Phase III data from Moderna and MSD, which validate cancer vaccines as a broader drug class.